Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T41515
|
||||
| Former ID |
TTDR01438
|
||||
| Target Name |
mRNA of FGFR4
|
||||
| Gene Name |
FGFR4
|
||||
| Synonyms |
mRNA of CD334; mRNA of FGFR-4; mRNA of Fibroblast growth factor receptor 4; FGFR4
|
||||
| Target Type |
Research
|
||||
| Disease | Obesity [ICD9: 278; ICD10: E66] | ||||
| Retinoblastoma [ICD10: C69.2] | |||||
| Function |
Receptor for acidic fibroblast growth factor. Does not bind tobasic fibroblast growth factor. Binds FGF19.
|
||||
| BioChemical Class |
Target of antisense drug
|
||||
| Target Validation |
T41515
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.10.1
|
||||
| Sequence |
MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRA
ERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDS LTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTP TIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLD VLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFP YVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTA AAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSL ESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQ VVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVC TQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGM QYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEA LFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYG LMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDS VFSHDPLPLGSSSFPFGSGVQT |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | ISIS-FGFR4 | Drug Info | Preclinical | Obesity | [1] |
| PD-0183812 | Drug Info | Terminated | Retinoblastoma | [2] | |
| Inhibitor | PD-0183812 | Drug Info | [3] | ||
| Ro-4396686 | Drug Info | [4] | |||
| Pathways | |||||
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | FGF signaling pathway | ||||
| Pathway Interaction Database | FGF signaling pathway | ||||
| Reactome | PI3K Cascade | ||||
| PIP3 activates AKT signaling | |||||
| FGFR4 ligand binding and activation | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Phospholipase C-mediated cascade | |||||
| FRS-mediated FGFR4 signaling | |||||
| FGFR4 | |||||
| FGFR4 | |||||
| Negative regulation of FGFR4 signaling | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
| PIP3 activates AKT signaling | |||||
| Signaling by FGFR | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130) | ||||
| REF 3 | J Med Chem. 2000 Nov 30;43(24):4606-16.Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. | ||||
| REF 4 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. Epub 2006 Feb 3.Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.